Biogen 1st-qtr misses sales expectations but beats on EPS
US biotech major Biogen (Nasdaq: BIIB) saw its shares slip 2% in pre-market trading, after the company posted first-quarter 2016 financial results that missed analysts’ sales expectations. However, by mid-morning the stock was up 4.7% at $278.44
Revenue rose 6.6% to $2.73 billion from $2.56 billion, missing the FactSet consensus forecasts of $2.74 billion, boosted by growing demand for its multiple sclerosis treatment Tecfidera (dimethyl fumarate).
Net income attributable to the U.S. biotechnology company rose to $970.9 million, or earnings per share of $4.43 per share, in the first quarter ended March 31, from $822.5 million, or $3.49 per share, a year earlier. On an adjusted basis, the company earned $4.79 per share, compared with the FactSet consensus of $4.44.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze